within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AE07_Moxifloxacin;

model Moxifloxacin
  extends Pharmacolibrary.Drugs.ATC.S.S01AE07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01AE07</td></tr><td>route:</td><td>ocular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Moxifloxacin is a fourth-generation fluoroquinolone antibiotic used for the treatment of bacterial infections. It is active against a broad spectrum of Gram-positive and Gram-negative pathogens and is commonly used to treat respiratory tract infections, skin infections, and certain types of conjunctivitis. Moxifloxacin with ATC code S01AE07 refers specifically to its ophthalmological (eye drop) use. The drug is approved for use in many countries and is generally well tolerated.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single and repeated topical ocular administration.</p><h4>References</h4><ol><li><p>Robertson, SM, et al., &amp; Dahlin, DC (2005). Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. <i>Survey of ophthalmology</i> 50 Suppl 1 S32–S45. DOI:<a href=\"https://doi.org/10.1016/j.survophthal.2005.07.001\">10.1016/j.survophthal.2005.07.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16257309/\">https://pubmed.ncbi.nlm.nih.gov/16257309</a></p></li><li><p>Ferreira, KSA, et al., &amp; Lira, RPC (2017). Ocular delivery of moxifloxacin-loaded liposomes. <i>Arquivos brasileiros de oftalmologia</i> 81(6) 510–513. DOI:<a href=\"https://doi.org/10.5935/0004-2749.20180090\">10.5935/0004-2749.20180090</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30231158/\">https://pubmed.ncbi.nlm.nih.gov/30231158</a></p></li><li><p>Proksch, JW, &amp; Ward, KW (2010). Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 26(5) 449–458. DOI:<a href=\"https://doi.org/10.1089/jop.2010.0054\">10.1089/jop.2010.0054</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20874668/\">https://pubmed.ncbi.nlm.nih.gov/20874668</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Moxifloxacin;
